ArticleDrug delivery and translational research2023
Emerging immunotherapeutics for immune activation and tolerance.
Ryan M Pearson, Abhinav P Acharya, James J Moon
Abstract readEditorial
In one paragraphArticle in Drug delivery and translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
3 authors.
Ryan M PearsonDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine Street, Baltimore, MD, 21201, USA. rpearson@rx.umaryland.edu.
Abhinav P AcharyaChemical Engineering, School for the Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, AZ, 85281, USA.
James J MoonDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, 48109, USA.
Funding
Restoring the Immunogenicity of Head and Neck CancerR01DE026728 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Yu Leo Lei, James J. Moon · 2018 to 2026
$4.3MEngineered Nano-formulations for STING ActivationR01DE031951 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Yu Leo Lei, James J. Moon · 2022 to 2026
$3.1MNew Engineering Strategy for Harnessing Immune System against Head and Neck CancerR01DE030691 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LEI, YU LEO, MOON, JAMES J. · 2021 to 2025
$2.9MBiomaterials for modulating the gut microbiome for immune activationR01CA271799 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI James J. Moon, Deepak Nagrath · 2022 to 2026
$2.7MNovel nano-vaccine technology for inducing immunity against gliomasR01NS122536 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G, MOON, JAMES J. · 2021 to 2025
$2.6MNovel biomaterials for IBD treatmentR01DK125087 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAMADA, NOBUHIKO, MOON, JAMES J. · 2020 to 2023
$2.5MTuning Biomaterials-immune cell interactions for treatment of glioblastoma multiformeR01EB022563 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2016 to 2019
$1.7MNCI NIH HHS R01 CA271799NIBIB NIH HHS R01 EB022563NIDCR NIH HHS R01 DE026728NIDCR NIH HHS R01 DE030691NIDCR NIH HHS R01 DE031951NIDDK NIH HHS R01 DK125087NINDS NIH HHS R01 NS122536
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Immunotherapy
Identifiers
PMID37079190
PMCPMC10478029
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390